L-chicoric acid inhibits human immunodeficiency virus type 1 integration in vivo and is a noncompetitive but reversible inhibitor of HIV-1 integrase in vitro

被引:49
作者
Reinke, RA
Lee, DJ
Mcdougall, BR
King, PJ
Victoria, J
Mao, YQ
Lei, XY
Reinecke, MG
Robinson, WE
机构
[1] Univ Calif Irvine, Dept Pathol, Irvine, CA 92697 USA
[2] Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA
[3] Texas Christian Univ, Dept Chem, Ft Worth, TX 76129 USA
关键词
real-time polymerase chain reaction; acquired immune deficiency syndrome; experimental therapeutics; biochemistry; steady-state kinetic analyses; provirus;
D O I
10.1016/J.VIROL.2004.06.005
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The human immunodeficiency virus (HIV) integrase (IN) must covalently join the viral cDNA into a host chromosome for productive HIV infection. L-Chicoric acid (L-CA) enters cells poorly but is a potent inhibitor of IN in vitro. Using quantitative real-time polymerase chain reaction (PCR), L-CA inhibits integration at concentrations from 500 nM to 10 muM but also inhibits entry at concentrations above I muM. Using recombinant HIV IN, steady-state kinetic analyses with L-CA were consistent with a noncompetitive or irreversible mechanism of inhibition. IN, in the presence or absence Of L-CA, was successively washed. Inhibition of IN diminished, demonstrating that L-CA was reversibly bound to the protein. These data demonstrate that L-CA is a noncompetitive but reversible inhibitor of IN in vitro and of HIV integration in vivo. Thus, L-CA likely interacts with amino acids other than those which bind substrate. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:203 / 219
页数:17
相关论文
共 91 条
[61]   Viral entry as the primary target for the anti-HIV activity of chicoric acid and its tetra-acetyl esters [J].
Pluymers, W ;
Neamati, N ;
Pannecouque, C ;
Fikkert, V ;
Marchand, C ;
Burke, TR ;
Pommier, Y ;
Schols, D ;
De Clercq, E ;
Debyser, Z ;
Witvrouw, M .
MOLECULAR PHARMACOLOGY, 2000, 58 (03) :641-648
[62]   Inhibitors of human immunodeficiency virus integrase [J].
Pommier, Y ;
Neamati, N .
ADVANCES IN VIRUS RESEARCH, VOL 52, 1999, 52 :427-458
[63]  
Porter K, 2001, BRIT MED J, V322, P1087, DOI 10.1136/bmj.322.7294.1087
[64]   Natural selection results in conservation of HIV-1 integrase activity despite sequence variability [J].
Reinke, R ;
Steffen, NR ;
Robinson, WE .
AIDS, 2001, 15 (07) :823-830
[65]   Dicaffeoyltartaric acid analogues inhibit human immunodeficiency virus type 1 (HIV-1) integrase and HIV-1 replication at nontoxic concentrations [J].
Reinke, RA ;
King, PJ ;
Victoria, JG ;
McDougall, BR ;
Ma, GX ;
Mao, YQ ;
Reinecke, MG ;
Robinson, WE .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (17) :3669-3683
[66]  
ROBINSON WE, 1989, J ACQ IMMUN DEF SYND, V2, P33
[67]  
Robinson WE, 1998, INFECT MED, V15, P129
[68]  
Robinson WE, 1998, ANTIVIR RES, V39, P101, DOI 10.1016/S0166-3542(98)00037-0
[69]   Inhibitors of HIV-1 replication that inhibit HPV integrase [J].
Robinson, WE ;
Reinecke, MG ;
AbdelMalek, S ;
Jia, Q ;
Chow, SA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (13) :6326-6331
[70]  
Robinson WE, 1996, MOL PHARMACOL, V50, P846